Fake reviews are a multibillion-dollar quicksand — here’s how to avoid getting sucked in
For many, a string of glowing reviews, or the mark of five golden stars, usually seals the deal in a purchase decision. But what’s real and what’s phony?
CNBC Daily Open: For the S&P, the last mile’s the longest
The S&P 500’s tantalizingly close to an all-time high. The index added 0.04% yesterday to close at 4,783.35, just about 10 points away from its record close.
Fund managers turn cautious on European stocks, BofA survey shows — here’s why
Fund managers strike a cautious tone on the prospects of the European economy — and stock market — going into 2024, but see some opportunities.
Piper Sandler reveals its top 3 biotech stock picks for 2024 — and gives one 90% upside
“After another difficult year, there are signs that biotech is recovering into 2024,” the investment bank says, citing the prospect of interest rate cuts.
Could a bitcoin ETF approval be a sell-the-news event? Here’s what to expect if it happens
A bitcoin ETF approval is expected in the coming weeks, but the market may be a little overheated. Here’s what to expect of it happens.
Cathie Wood’s ARK invests in ProShares Bitcoin Strategy ETF after exiting GBTC: CNBC Crypto World
CNBC Crypto World features the latest news and daily trading updates from the digital currency markets and provides viewers with a look at what’s ahead with high-profile interviews, explainers, and unique stories from the ever-changing crypto industry….
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might have in store.
Russia’s Lavrov claims Ukraine’s Western allies are quietly changing strategy in bid to end conflict
Russia’s foreign minister claimed the strategic defeat of his country had “failed miserably,” forcing the West to change strategy.
